Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAGIO: GB-102 in Wet AMD
NCT03249740Phase 1Completed
- Sponsor
- CalciMedica
- Start
- Aug 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sunitinib in neovascular age-related macular degeneration (NVAMD) (4 arms), sponsored by CalciMedica. Primary endpoints: Occurrence of ocular and nonocular adverse events at 12 months and Change from baseline in best corrected visual acuity by ETDRS at 12 months. Started Aug 2017; status: completed.
02
Drugs
sunitinib
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03249740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03249740.